0IIM Stock Overview
A pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C).
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 5/6 |
Past Performance | 0/6 |
Financial Health | 1/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
Esperion Therapeutics, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$2.25 |
52 Week High | US$3.37 |
52 Week Low | US$0.71 |
Beta | 0.99 |
11 Month Change | 4.80% |
3 Month Change | -16.36% |
1 Year Change | 60.57% |
33 Year Change | -90.82% |
5 Year Change | n/a |
Change since IPO | -97.00% |
Recent News & Updates
Recent updates
Shareholder Returns
0IIM | GB Pharmaceuticals | GB Market | |
---|---|---|---|
7D | -20.2% | 0.5% | 1.7% |
1Y | 60.6% | 11.4% | 8.9% |
Return vs Industry: 0IIM exceeded the UK Pharmaceuticals industry which returned 11.4% over the past year.
Return vs Market: 0IIM exceeded the UK Market which returned 8.9% over the past year.
Price Volatility
0IIM volatility | |
---|---|
0IIM Average Weekly Movement | 14.7% |
Pharmaceuticals Industry Average Movement | 8.1% |
Market Average Movement | 4.8% |
10% most volatile stocks in GB Market | 11.2% |
10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0IIM's share price has been volatile over the past 3 months.
Volatility Over Time: 0IIM's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2008 | 240 | Sheldon Koenig | www.esperion.com |
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company’s products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C.
Esperion Therapeutics, Inc. Fundamentals Summary
0IIM fundamental statistics | |
---|---|
Market cap | US$413.02m |
Earnings (TTM) | -US$86.51m |
Revenue (TTM) | US$229.74m |
1.8x
P/S Ratio-4.8x
P/E RatioIs 0IIM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
0IIM income statement (TTM) | |
---|---|
Revenue | US$229.74m |
Cost of Revenue | US$109.82m |
Gross Profit | US$119.92m |
Other Expenses | US$206.43m |
Earnings | -US$86.51m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.46 |
Gross Margin | 52.20% |
Net Profit Margin | -37.65% |
Debt/Equity Ratio | -184.1% |
How did 0IIM perform over the long term?
See historical performance and comparison